The effectiveness of intranasal corticosteroids in treating chronic rhinosinusitis and its effect on the microbiome
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by An Duc Thien Le |
Posted on May 24th, 2023
|
To alleviate the consistent inflammation caused by chronic sinusitis, intranasal corticosteroids are administered. However, there is little evidence about the efficacy in the pediatric population. Plus, the effect of intranasal corticosteroids on the nasal microbiome is unknown. A study, recently published in the Journal of the American Medical Association, had investigated how the effect intranasal corticosteroids has on the quality of life of children with chronic sinusitis.
The clinical trial included 66 children between the age of 4 and 8 years old who were diagnosed with chronic sinusitis because they have experienced 2 of the following symptoms for at least 12 weeks before enrolling into the study: nasal congestion, nasal discharge, facial pain, pressure, or cough. 66.7% of the study participants were diagnosed with asthma, and 46% experienced food allergy during their infancy. The patients were randomly selected to be treated with either mometasone with 0.9% sodium chloride or just the 0.9% sodium chloride. The intranasal solution was administered once a day with an atomizer for 12 weeks. Clinical effectiveness was assessed using the Sinus and Nasal Quality of Life Survey (SN-5), and sampling of the nasopharynx was performed for microbiome characterization and detection of innate lymphoid cells (ILC). The researchers found that mometasone significantly improved the quality of life, enhanced the microbiome richness, and reduced the amount of pro-inflammatory ILC3. There was no significant difference in the rate of adverse events between the 2 groups.
The clinical trial included 66 children between the age of 4 and 8 years old who were diagnosed with chronic sinusitis because they have experienced 2 of the following symptoms for at least 12 weeks before enrolling into the study: nasal congestion, nasal discharge, facial pain, pressure, or cough. 66.7% of the study participants were diagnosed with asthma, and 46% experienced food allergy during their infancy. The patients were randomly selected to be treated with either mometasone with 0.9% sodium chloride or just the 0.9% sodium chloride. The intranasal solution was administered once a day with an atomizer for 12 weeks. Clinical effectiveness was assessed using the Sinus and Nasal Quality of Life Survey (SN-5), and sampling of the nasopharynx was performed for microbiome characterization and detection of innate lymphoid cells (ILC). The researchers found that mometasone significantly improved the quality of life, enhanced the microbiome richness, and reduced the amount of pro-inflammatory ILC3. There was no significant difference in the rate of adverse events between the 2 groups.